Investor Presentation: First Nine Months of 2020
24
Investor presentation First nine months of 2020
Sales growth of 7% at CER, mainly driven by the Diabetes and
Obesity care segment
Novo Nordisk reported quarterly sales
DKK
billion
by therapy
Reported sales for the first
nine months of 2020
40
331250
Reported sales
CAGR1: 6.7%
Other Biopharm
Growth disorders
1%
Haemophilia 6%
(4.3%)¹
8%
4.3%1
Obesity
4%
1.5%1
7.9%1
Novo NordiskⓇ
Reported sales and growth breakdown for
the first nine months of 2020
Therapy
Sales
(mDKK)
Growth
Share of
growth
Long-acting insulin²
13,426
(13%)
(33%)
Premix insulin³
8,220
6%
8%
Fast-acting insulin
14,082
(1%)
(2%)
Human insulin
7,195
8%
9%
Total insulin
42,923
(3%)
(18%)
GLP-15
30,051
29%
107%
Other Diabetes care6
3,056
(4%)
(2%)
Total Diabetes care
76,030
8%
87%
Obesity care (SaxendaⓇ)
4,223
6%
4%
Diabetes and Obesity care
80,253
8%
91%
80%
Haemophilia7
7,522
(2%)
(2%)
Diabetes care
Growth disorders
5,872
13%
11%
(NorditropinⓇ)
Other Biopharm³
Biopharm
1,161
1%
0%
14,555
3%
9%
Total
94,808
7%
100%
5
0
Q3
Other
2010
NorditropinⓇ
Q3
2020
■Haemophilia
Diabetes and Obesity care
Sales of DKK 94.8 billion (+7%)
1 CAGR for 10-year period; 2 Comprises Tresiba®, XultophyⓇ and LevemirⓇ; 3 Comprises RyzodegⓇ and NovoMix®: 4 Comprises FiaspⓇ and NovoRapid: 5 Comprises Victoza®, Ozempic®, Rybelsus®; 6 Primarily NovonormⓇ, needles and GlucaGen® HypoKitⓇ;
7 Comprises Novo Seven®, Novo Eight®, NovoThirteen® Refixia®, and EsperoctⓇ8 Primarily Vagifem®, Activelle®, Macrilen® Note: Refixia® and NovoThirteenⓇ are launched as RebinynⓇ and TRETTENⓇ, respectively, in North America.
Note: Sales numbers are reported in Danish kroner; Growth is at constant exchange ratesView entire presentation